THERAPEUTIC EFFECT OF ADRIAMYCIN ENCAPSULATED IN LONG-CIRCULATING LIPOSOMES ON METH-A-SARCOMA-BEARING MICE

Long-circulating liposomes modified with a uronic-acid derivative, palmityl-D-glucuronide (PGlcUA), have been developed previously for the passive targeting of liposomes to tumor tissues. In this study, we examined the therapeutic effect of adriamycin (ADM) encapsulated in PGlcUA liposomes composed of dipalmitoylphosphatidylcholine (DPPC), cholesterol (Chol) and PGlcUA (molar ratio, 40/40/10) since this amount of PGlcUA was enough to endow liposomes with long-circulating activity. Long-circulating activity was also observed with palmityl-D-galacturonide (PgalUA) modified liposomes, suggesting that uronic acid plays an important role in preventing liposomes from being trapped in the reticuloendothelial system (RES). ADM was loaded in liposomes by a remote-loading method. Free or liposomal ADM was injected i.v. into BALB/c mice bearing s.c.-implanted Meth-A sarcoma. The liposomal formulation was efficient for reducing tumors, prolonging survival time and curing the animals, especially in the case of large tumors where free ADM was not. Furthermore, PGlcUA liposomes were more effective than conventional liposomes containing dipalmitoylphosphatidylglycerol (DPPG) instead of PGlcUA for prolonging survival time in mice. It might therefore be appropriate to use PGlcUA liposomes as the carriers of anticancer drugs. (C) 1994 Wiley-Liss, Inc.